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Protocol
AbstrACt
Objectives To test whether administration of the 
antifibrinolytic drug tranexamic acid (TXA) in patients with 
spontaneous intracerebral haemorrhage (SICH) leads to 
increased prevalence of diffusion-weighted MRI-defined 
hyperintense ischaemic lesions (primary hypothesis) or 
reduced perihaematomal oedema volume, perihaematomal 
diffusion restriction and residual MRI-defined SICH-related 
tissue damage (secondary hypotheses).
Design MRI substudy nested within the double-blind 
randomised controlled Tranexamic Acid for Hyperacute 
Primary Intracerebral Haemorrhage (TICH)-2 trial 
(ISRCTN93732214).
setting International multicentre hospital-based study.
Participants Eligible adults consented and randomised 
in the TICH-2 trial who were also able to undergo MRI 
scanning. To address the primary hypothesis, a sample 
size of n=280 will allow detection of a 10% relative 
increase in prevalence of diffusion-weighted imaging 
(DWI) hyperintense lesions in the TXA group with 5% 
significance, 80% power and 5% imaging data rejection.
Interventions TICH-2 MRI substudy participants will 
undergo MRI scanning using a standardised protocol 
at day ~5 and day ~90 after randomisation. Clinical 
assessments, randomisation to TXA or placebo and 
participant follow-up will be performed as per the TICH-2 
trial protocol.
Conclusion The TICH-2 MRI substudy will test whether 
TXA increases the incidence of new DWI-defined 
ischaemic lesions or reduces perihaematomal oedema or 
final ICH lesion volume in the context of SICH.
Ethics and dissemination The TICH-2 trial obtained ethical 
approval from East Midlands - Nottingham 2 Research 
Ethics Committee (12/EM/0369) and an amendment to 
allow the TICH-2 MRI sub study was approved in April 2015 
(amendment number SA02/15). All findings will be published 
in peer-reviewed journals. The primary outcome results will 
also be presented at a relevant scientific meeting. 
trial registration number ISRCTN93732214; Pre-results.
IntrODuCtIOn AnD rAtIOnAlE
Tranexamic acid (TXA) is an antifibrino-
lytic drug that binds reversibly to the lysine 
binding site of plasminogen/plasmin,1 
leading to potent inhibition of the interaction 
of plasmin with fibrin that results in reduced 
fibrinolysis. In the context of spontaneous 
intracerebral haemorrhage (SICH), it has 
been postulated that TXA will result in more 
strengths and limitations of this study
 ► MRI is incorporated into an international multicentre 
randomised controlled trial of tranexamic acid (TXA) 
in spontaneous intracerebral haemorrhage. This will 
be used to objectively assess the potential effects 
of TXA on cerebral ischaemia, which might not be 
visible using standard clinical imaging such as CT.
 ► This study also uses MRI to assess any potential 
beneficial effects of TXA on neurotoxicity and 
neuroinflammation.
 ► The inclusion of MRI necessitates the introduction 
of additional exclusion criteria, which increases the 
risk of under-recruitment and subsequent reduction 
of statistical power.
 ► A limitation of the recruitment process to 
the Tranexamic Acid for Hyperacute Primary 
Intracerebral Haemorrhage  2 MRI substudy is that 
recruitment took place after  randomisation. As a 
result, survivor bias may be a potential confounder, 
which we address by conducting regression 
analyses adjusting for baseline variables.
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rapid cessation of bleeding at the point of vessel rupture 
and hence limit haematoma expansion, a factor shown 
to be associated with both mortality and disability.2 The 
Tranexamic Acid for Hyperacute Primary Intracerebral 
Haemorrhage (TICH-2) trial is an international multi-
centre randomised controlled trial to test the hypoth-
esis that intravenous TXA reduces death and disability 
when given within 8 hours of SICH (ISRCTN93732214).3 
However, there are alternative mechanisms in addition 
to haemostatic by which TXA could alter the pathophys-
iology and hence outcome of the evolving brain injury 
that accompanies SICH via its interaction with the plas-
minogen activation axis.
First, patients with SICH are at risk of co-occurring 
cerebral ischaemic events and TXA could theoretically 
potentiate this risk by the inhibition of fibrin degrada-
tion. Diffusion-weighted imaging (DWI) MRI hyper-
intense lesions (DWIHLs), which are thought to be 
indicative of acute or subacute ischaemia, co-occur with 
SICH with a prevalence of 8%–35%4–7 and are associated 
with a higher risk of dependence or death at 3 months 
(OR 4.8; 95% CI 1.7 to 13.9; P=0.004).8 The mechanisms 
underlying the high prevalence of DWIHL in SICH 
are not known. Endothelial failure is thought to be a 
key event in the mechanism of small vessel disease and 
lacunar infarction.9 A sequential process of endothelial 
failure, non-occlusive wall-associated microthrombosis, 
vessel rupture, microbleeding and finally reactive occlu-
sive thrombosis leading to infarction has been proposed 
based on animal models.10 The inhibition of fibrin degra-
dation by TXA could potentiate this process by exacerba-
tion of microvascular thrombosis. Support for a possible 
potentiating effect of TXA on cerebral ischaemia comes 
from a meta-analysis of predominantly prolonged (>10 
days) TXA administration in spontaneous subarachnoid 
haemorrhage (SAH) which found pooled relative risk 
for reported cerebral ischaemia of 1.41 (95% CI 1.04 to 
1.91).11 However, multiple studies of TXA in a variety of 
other disease settings, including traumatic and sponta-
neous bleeding (non-SAH) showed no increase in cere-
bral ischaemia with TXA use.12–15
Second, there are potentially beneficial effects of TXA 
by modulation of the plasminogen activation cascade by 
reducing neurotoxicity and neuroinflammation.16–18 A 
study in surgical patients has shown that TXA attenuates 
the inflammatory response19 thought to be mediated by 
inhibition of the plasminogen activation cascade. Clin-
ical and biological markers of inflammatory response at 
presentation are predictors of early neurological dete-
rioration in SICH.20 Perihaematomal oedema (PHO) 
volume and diffusion properties have been proposed as 
biomarkers of the inflammatory response around SICH,21 
and levels of circulating matrix metalloproteinase-3 are 
independently associated with PHO volume.22 PHO 
increases rapidly during the first 48 hours and peaks 
towards the end of the second week following SICH.23 MRI 
DWI of PHO most commonly shows elevated diffusion24 25 
implying that PHO results from increased permeability 
of the neurovascular unit or alterations in the extravas-
cular ultrastructural environment rather than ischaemia, 
although in cases where restricted diffusion is detected in 
PHO, an association with poor clinical outcome has been 
observed.26
In the TICH-2 MRI substudy, MRI scans will be 
acquired in a subgroup of the TICH-2 trial population 
on day 5 after randomisation (acceptable range day 2 to 
day 14, referred to hereafter as the day 5 scan) and day 
90 after randomisation (acceptable range day 83 to day 
110, referred to as the day 90 scan). The MRI data will be 
used to test a primary hypothesis regarding treatment-re-
lated differences in DWIHL prevalence. It will also allow 
secondary analyses of treatment effects on PHO volume 
and diffusion properties and SICH-related tissue damage 
at day 90.
Primary hypothesis
Prevalence of remote DWI hyperintense lesions on the day 
5 MRI scan will be greater in the TXA group compared 
with controls.
secondary hypotheses
1. Perihaematomal oedema volume and perihaemato-
mal diffusion restriction on day 5 MRI scan will be 
reduced in the TXA group compared with controls.
2. SICH-related tissue damage defined on the day 90 
MRI scan will be reduced in the TXA group com-
pared with controls, controlling for initial haematoma 
volume.
We will test whether imaging markers of coexisting 
small vessel disease (cerebral microbleeds (CMBs) and 
white matter hyperintensities (WMHs) of presumed 
vascular origin) and imaging markers of cerebral 
amyloid angiopathy (CAA) (strictly lobar CMB, cortical 
superficial siderosis) are associated with the presence of 
DWIHL in TXA treated patients.
DEsIgn AnD mEthODs
Patient population
The recruitment process is summarised in figure 1. Patients 
recruited to the main TICH-2 trial according to the TICH-2 
trial inclusion and exclusion criteria3 (see online supple-
mentary information) at centres participating in the 
TICH-2 MRI substudy will be invited to participate in the 
TICH-2 MRI substudy provided they meet the additional 
following inclusion/exclusion criteria.
 ► Additional TICH-2 MRI study inclusion criteria:
(1) Participant or delegate freely gives informed 
consent to participate in the TICH-2 MRI 
substudy or participants within the TICH-2 trial 
who have an MRI scan performed for clinical 
purposes within the MRI substudy time windows 
using a protocol consistent with the MRI substudy 
(TICH-2 trial consent includes submission of 
relevant clinical data which includes imaging 
data).
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(2) Able to undergo MRI scanning.
 ► Additional TICH-2 MRI substudy exclusion criteria:
(1) Contraindication to MRI scan (eg, non-MRI-com-
patible implant, intraocular/intracranial metallic 
device or fragment, claustrophobia, etc).
(2) Clinical instability (for example cardiorespira-
tory or neurological instability) such that MRI 
scan would introduce additional clinical risk.
randomisation
Participants are randomised into the main TICH-2 study 
as described previously.3 Recruitment into the TICH-2 
MRI substudy can occur at any time between the point 
of initial recruitment to the main TICH-2 study (preran-
domisation) up to day 7 after randomisation. Blinding to 
treatment allocation is maintained throughout the course 
of both the TICH-2 main and MRI substudy.
Intervention
The TICH-2 trial intervention has been described previ-
ously.3 In brief, participants are randomised (1:1) to 
intravenous tranexamic acid (1 g in 100 mL intravenous 
bolus loading dose followed by 1 g in 250 mL infusion 
over 8 hours) or placebo (0.9% saline using identical 
administration regime).
MRI scanning is performed on day 5 (acceptable 
range day 2 to day 14) and day 90 (acceptable range 
day 83 to day 110) postrandomisation. The MRI acqui-
sition protocol (table 1) complies with the essential 
imaging sequences specified by the Standards for 
Reporting Vascular Neuroimaging standards9 and 
includes two-dimensional (2D) axial, T2-weighted 
images, T2*-weighted images, T2-weighted fluid-atten-
uated inversion recovery (FLAIR) images, DWI and a 
three-dimensional (3D) T1-weighted volume acquisi-
tion. Axial 2D T1-weighted images are to be included 
if the 3D T1-weighted volume is significantly motion 
degraded and manufacturer optimised susceptibility 
weighted imaging is to be included if available.
Outcomes
Primary outcome
 ► Prevalence of remote DWIHL on the day 5 MRI scan.
Secondary outcomes
 ► Perihaematomal oedema volume and perihaemat-
omal diffusion restriction on the day 5 MRI scan.
 ► SICH-related tissue damage (the combined volume 
of the residual haematoma cavity and surrounding 
FLAIR hyperintensity) determined on the day 90 MRI 
scan.
Methodology for extraction of the imaging outcome 
measures is summarised in figure 2. DWI scans will 
be analysed for presence, number and distribution 
of DWIHL. A semiautomated method for quantifica-
tion of DWIHL will be developed and validated using 
a subset of patients. It will be subsequently employed 
to identify candidate lesions based on shape and inten-
sity features. Candidate lesions will then be accepted or 
rejected by at least two expert readers independently. 
Only DWIHL that are confirmed of low diffusion on 
the derived apparent diffusion coefficient maps and 
spatially remote from the index ICH (<20 mm) will be 
included as previously.6
A fully automated segmentation method27 will exploit 
the T2, T2* and FLAIR images to segment the haema-
toma and PHO on day 5 MRI scan (limited for secondary 
hypothesis 1 to scans performed up to and including day 
7), from which volume and quantification of the diffu-
sion properties of PHO can be derived (figure 3). FLAIR 
images will be used to determine the volume of final 
haematoma cavity and surrounding hyperintensity on the 
day 90 scan using semiautomated segmentation super-
vised by experienced image analysts. T1-weighted images 
will be used to determine brain parenchymal volume on 
the day 90 scan.
WMH will be evaluated on FLAIR and T2-weighted 
images using an established 4-point scale28 and auto-
mated WMH segmentation will be used for WMH 
Figure 1 TICH-2 MRI substudy flowchart. Details of 
participant flow for the TICH-2 trial, including the schedule 
for randomisation, treatment, cranial CT, clinical assessments 
and non-MRI follow-up assessments have been described 
in Sprigg et al.3 TICH-2, Tranexamic Acid for Hyperacute 
Primary Intracerebral Haemorrhage 2 trial. 
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volume calculation and creation of a distribution map of 
WMH. CMB number and distribution will be rated using 
Microbleed Anatomical Rating Scale and used for classi-
fication of ICH patients into probable CAA and non-CAA 
groups.29
sample size estimates
Primary hypothesis
Based on previous studies finding prevalence of DWIHL 
of 20% in SICH, we performed calculations for sample 
size to allow us to detect different percentage increases in 
DWIHL prevalence in the TXA group above a 20% base-
line, using the sample size formula for prevalence:
 n =
(
z2
1−α2
)
·p(1−p)
m2
, (1)
where z=CI, P=prevalence and m=margin of error 
(standard is 5%). Assuming a 10% relative increase in 
prevalence of DWIHL (ie, from 20% to 22%) in the TXA 
group, with 5% significance and 80% power, a sample size 
of 264 is required. Allowing 5% imaging data rejection 
(eg, due to excessive patient motion), a sample size of 
280 is required.
Secondary hypotheses
Our pilot data from the TICH-1 study30 showed that 
for every 1 mL of SICH volume, the mean relative PHO 
volume increased between the day 0 and day 2 CT scan 
by 0.29 mL (SD, SD 0.34) in TXA-treated patients and by 
0.41 mL (SD 0.27 mL) in the placebo group. Assuming 
a similar effect size is present on day 5 MRI scan using 
the sample size proposed for the main hypothesis 
(n=280), we will be able to detect a group difference 
in the increase in relative PHO with power of 0.89 and 
α=0.05 (independent samples t-test, two tailed).
statistical analyses
Group baseline characteristics will be compared between 
the TICH-2 MRI substudy and the main TICH-2 trial to 
Table 1 MRI acquisition parameters
DWI T2-FLAIR T2* GRE 2D
SWI 3D (see  
note 1) 3D T1-volume T2
2D T1 (see 
note 2)
Orientation Axial Axial Axial Use standard 
manufacturer 
specific SWI 
protocol from 
manufacturer’s 
protocol tree (ie, 
SWAN (General 
Electric); VEN_
BOLD (Philips); 
SWI (Siemens))
Sagittal Axial Axial
Plane 2D—EPI 2D 2D 3D 2D 2D
TE (ms) Minimum 125–140 20–30
(15–40)
Minimum 85–100 10–14
TR (ms) Minimum 11 000 300–1000 Minimum 3000–5600 600–650
TI (ms) NA 2800 NA 450– 1000
(or no inversion 
on old General 
Electric 
FSPGR)
NA NA
Slice thickness 
(mm)
≤4.0 ≤4.0 3
(3-5)
1 mm isotropic 
voxels
(1.25 mm)
≤4.0 ≤4.0
Slice gap (mm) ≤0.4 ≤0.4 ≤0.3
(0–1)
NA ≤0.4 ≤0.4
Acquisition 
matrix (RFOV 
acceptable)
96–128 180–256
(180-512)
180–256 128–256 180–256
(180-512)
180–256
FOV (mm) 230–240 230–240 230–240 224–256 230–240 230–240
Flip angle 
(excitation)
90° 90° 15–60° 8–15° 90° 90°
Flip angle 
(refocusing)
180° 180° NA NA 180° 180°
b-value 1000 NA NA NA NA NA
Number of slices 32–42 32–42 32–42 180–192
(128–256)
32–42 32–42
Preferred parameters are listed, with acceptable range of values given in brackets for sites where the preferred parameters cannot be 
achieved for technical reasons . 
Note 1: If available.
Note 2: Only required if 3D T1-volume acquisition is degraded by patient motion.
DWI, diffusion-weighted image; EPI, echo-planar imaging; FLAIR, fluid-attenuated inversion recovery; FOV, field of view; FSPGR, fast spoiled 
gradient-echo; GRE 2D, gradient echo two dimensional; NA, not applicable; RFOV, rectangular field of view; SWI 3D, susceptibility weighted 
imaging three dimensional; TE, echo time; TI, inversion time; TR, repetition time. 
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examine the extent to which the TICH-2 MRI substudy 
participants are representative of the TICH-2 trial popu-
lations. To analyse the primary hypothesis, presence of 
DWIHL post-SICH will be compared between treatment 
groups using a binary logistic regression with adjustment 
for a selection of baseline covariates; age, time from onset 
to randomisation, stroke severity (using National Insti-
tutes of Health Stroke Scale), mean systolic blood pres-
sure, known history of antiplatelet treatment and baseline 
haematoma volume.
To test the secondary hypotheses, a group comparison 
test of PHO volume, PHO diffusion metrics and day 90 
Figure 2 Summary of image processing and outputs in the TICH-2 MRI substudy. 3D, three dimensional; ADC, apparent 
diffusion coefficient; CMB, cerebral microbleed; DWI, diffusion-weighted image; DWIHL, diffusion-weighted image hyperintense 
lesion; FLAIR, fluid-attenuated inversion recovery; MNI, montreal neurological institute; PHO, perihaematomal oedema; 
ROI, region of interest; SWI, susceptibility weighted imaging; TICH-2, Tranexamic Acid for Hyperacute Primary Intracerebral 
Haemorrhage 2 trial; WMHL, white matter hyperintense lesion. 
Figure 3 Measurement of PHO volume and ADC. (A) Axial FLAIR image in native T1 space showing the PHO delineation from 
which the PHO volume can be derived. (B) ADC map in native T1 space. PHO ADC values are calculated from the voxels within 
the PHO delineation in the ADC map. ADC, apparent diffusion coefficient; FLAIR, fluid-attenuated inversion recovery; PHO, 
perihaematomal oedema. 
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combined haematoma cavity and surrounding FLAIR 
hyperintensity volume between participants in the TXA 
and control treatment groups will be performed. Other 
proposed analyses will include analyses of association 
between presence of DWIHL and imaging markers of 
small vessel disease (CMB, WMH) and likely diagnostic 
classification for CAA (based on CMB distribution and 
presence of superficial siderosis) and exploratory anal-
yses of associations between imaging outcomes and 
clinical outcomes, with adjustment for haematoma 
expansion. All regression analyses will be adjusted for 
the covariates listed previously.
study organisation and funding
The TICH-2 MRI substudy is funded by a grant from British 
Heart Foundation (grant reference PG/14/96/31262). 
The TICH-2 trial is funded by a grant from the UK 
National Institute for Health Research Health Technology 
Assessment programme (project code 11_129_109). 
The TICH-2 trial (ISRCTN50867461) obtained ethical 
approval from Nottingham-2 Research Ethics Committee 
on 19/11/12 and an amendment to allow the TICH-2 
MRI substudy was approved on 21/04/2015 (amend-
ment number SA02/15). The University of Nottingham 
acts as the trial sponsor. The trial steering committee 
for the TICH-2 trial oversees the TICH-2 MRI substudy. 
Data monitoring for the TICH-2 trial is performed by an 
independent data monitoring committee.3 Recruitment 
into the MRI substudy started in July 2015 and finished in 
September 2017.
DIsCussIOn
Tranexamic acid may have biological effects in the brain 
tissue that could alter the outcome in SICH patients, 
independent to the postulated effects on haematoma 
expansion. The main theoretical concern is that the 
haemostatic effects of TXA might increase the risk of 
cerebral ischaemia. Understanding these effects is vital, 
particularly if the results of ongoing trials31 show an 
effect of TXA on outcome that is not (or only partially) 
explained by an effect of TXA on haematoma expansion. 
This study allows us to quantify treatment-related brain 
changes (particularly prevalence of ischaemic lesions, 
PHO volume and diffusion characteristics and late post-
SICH tissue damage) in SICH patients in the context of a 
multicentre randomised controlled trial. If the results of 
the ongoing trials support the use of TXA, then the oppor-
tunity to study the potential therapeutic effects of TXA in 
acute cerebrovascular brain injury in a controlled trial is 
unlikely to occur again. By including imaging markers of 
small vessel disease and CAA in the analysis of DWIHL 
burden, we will be able to test whether there is a subgroup 
of patients at risk of DWIHL following TXA treatment for 
SICH, which will inform future studies of TXA in SICH 
and could ultimately influence clinical practice. If the 
study shows a beneficial effect of TXA on PHO, then this 
study may trigger studies of TXA in other acute brain 
pathologies associated with oedema and inflammation.
A limitation of the recruitment process to the 
TICH-2 MRI substudy is that recruitment took place 
after randomisation. As a result, survivor bias could be 
a confounder as a treatment allocation-related impact 
on survival of one group over the other could lead to 
imbalance between the groups entering into the study. 
Recruitment to the MRI substudy prerandomisation was 
discussed by the investigators during the study design 
but was considered to be impractical due to the require-
ment for additional information to be delivered to the 
participant/relatives and additional consent preran-
domisation which could potentially lead to delays to 
randomisation for the main TICH-2 trial. To identify a 
potential survivor bias, we will compare group baseline 
characteristics between the participants in the TICH-2 
MRI substudy and the main TICH-2 trial. To attempt to 
control for possible imbalances, we conduct the regres-
sion analyses adjusting for prespecified baseline vari-
ables, as detailed in the ‘statistical analyses’ section.
summAry AnD COnClusIOn
TXA is a widely available and inexpensive antifibrino-
lytic drug, which has the potential of reducing neuro-
toxicity and neuroinflammation in SICH. However, it is 
also possible that it may potentiate the risk of ischaemic 
events. The TICH-2 MRI substudy will assess the effective-
ness of TXA in reducing inflammatory response, while 
also determining whether there is an increased risk of 
ischaemic events following its administration. This will 
inform future studies of TXA and, if found to be effective 
and safe, have an important impact in clinical practice.
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